Dermatology | Preclinical Developments

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University

Lead Product(s): WEG232

Therapeutic Area: Dermatology Product Name: WEG232

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: George Washington University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2020

Details:

Hoth Therapeutics has expanded its research agreement with the George Washington University to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

Lead Product(s): VNLG 152

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

Management provides pipeline update for assets including BioLexa Platform (Dermatological), VNLG-152 (Dermatological), WEG-232 (Dermatological), VaxCelerate (COVID-19), Novel Peptide Therapeutic (COVID-19), AEA-loaded Z-pods™ (Lupus), Exon Skipping Approach (Allergic Disease).

Kymera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

Kymera is developing potent and selective orally administered IRAK4 degraders for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven autoimmune and autoinflammatory diseases.

Chelexa Biosciences

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

Lead Product(s): Antimicrobial therapy

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Hoth Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 18, 2020

Details:

Hoth Therapeutics has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, antimicrobial therapy focused on treating atopic dermatitis. The agreement is an extension to the previously executed sublicense agreement with Chelexa Biosciences.

Tetra BioPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Tetra Receives its 4th FDA Orphan Drug Designation

Lead Product(s): Tetrahydrocannabinol,Cannabidiol

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

PP004 will be used for management of pain and itch in EB, symptoms that, despite a range of current treatment strategies, significantly affect the quality of life in EB patients.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Commences Next Phase of VNLG-152 Study

Lead Product(s): Retinamide

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2020

Details:

As part of the next phase of this study, the assay will be tested to explore whether VNLG-152 is capable of blocking this inflammatory response.

Isoprene Pharmaceuticals

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals

Lead Product(s): Retinamide

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Hoth Therapeutics

Deal Size: $0.1 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 30, 2020

Details:

Through this agreement, Hoth Therapeutics acquires the full licensing rights of VNLG-152 novel retinamides for the treatment of dermatological diseases.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment

Lead Product(s): WEG232

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2020

Details:

WEG232 topical treatment showed a 71% reduction in SD-Rats with erlotinib-induced facial rash/hair loss.

Hoth Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

Lead Product(s): Antimicrobial therapy

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis.

Bayer HealthCare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone ...

Lead Product(s): Staphylococcus epidermidis strain

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future License Agreement.

Find

Find Novel Dermatology Drugs in Preclinical Development

Preclinical

Product Type

Companies

Hoth Therapeutics

Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University

Hoth Therapeutics

Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

Kymera Therapeutics

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis

Chelexa Biosciences

Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

Tetra BioPharma

Tetra Receives its 4th FDA Orphan Drug Designation

Hoth Therapeutics

Hoth Therapeutics Commences Next Phase of VNLG-152 Study

Isoprene Pharmaceuticals

Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals

Hoth Therapeutics

Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment

Hoth Therapeutics

Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

Bayer HealthCare

Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone ...